Karim Chamie, MD, explains how he might approach immunotherapy in patients with MIBC if it were available for use in both the neoadjuvant and adjuvant settings in the future.
FDA approves nivolumab plus cisplatin/gemcitabine in urothelial carcinoma
March 7th 2024The approval is based on data from the phase 3 CheckMate-901 trial, which demonstrated improved overall survival and progression-free survival with the nivolumab-combination therapy vs cisplatin/gemcitabine alone.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.